Deep Dive
来自我们记者的行业洞察
FDA Decision on Premature Birth Drug Withdrawal Looms: Patients and Regulators in Focus
The U.S. FDA is expected to decide soon on whether to withdraw Makena, a drug for preventing premature birth. The drug did not show a reduction in preterm birth risk in 2019 confirmatory trials, but its withdrawal would leave some high-risk pregnant women without the only approved preventive option. The FDA advisory committee recommended withdrawal by a vote of 14 to 1, with the final decision to be made by Commissioner Califf and Chief Scientist Bumpus. The controversy also involves deeper issues such as racial disparities, regulation of compounded formulations, and insufficient investment in preterm birth research.
The Rise of a New Generation of Biotech Leaders: Can They Reshape How Drug Startups Are Built?
A new generation of biotech entrepreneurs, including Stanford PhD Kevin Parker, discovered a lack of systematic guidance during their entrepreneurial journeys and launched a 'founder-led biotech' movement. Through communities, summits, and mentorship programs, they help academic scientists overcome startup barriers. Despite challenges such as inexperience, this movement has the potential to broaden industry boundaries and foster more diverse drug development.
IPO window narrows for medical technology companies, financing paths face re-evaluation
Affected by multiple factors such as the pandemic, geopolitical conflicts, inflation, and interest rate hikes, the IPO window for medical technology companies has narrowed sharply, with the number of applications in 2022 declining significantly year-over-year. Analytical institutions expect that the market is unlikely to recover in the short term, and companies may turn to alternative paths such as private financing, bridge loans, or mergers and acquisitions, while facing the dual challenges of valuation downgrades and a capital winter.
